Why the study?
Does torasemide improve safety, tolerability, and efficacy compared to furosemide or other diuretics in patients with NYHA class II-III chronic heart failure?
Population
1,377 patients with New York Heart Association (NYHA) class II–III chronic heart failure (CHF).
Comparison
Torasemide 10 mg/day orally on top of existing… vs Furosemide 40 mg/day orally or other diuretics…
Design
Cohort, non-randomised, open-label
Follow-up
12 months
Authors
Loading...
Should not yet change diuretic choice in HF; leaves open randomized confirmation of torasemide mortality benefit.
Does torasemide improve safety, tolerability, and efficacy compared to furosemide or other diuretics in patients with NYHA class II-III chronic heart failure?
In patients with NYHA class II-III chronic heart failure, torasemide was associated with lower mortality, greater functional improvement, and a lower incidence of hypokalemia compared to furosemide or other diuretics.
Cosín et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: